179 related articles for article (PubMed ID: 7388786)
1. Active transport of methotrexate from cerebrospinal fluid in humans.
Bode U; Magrath IT; Bleyer WA; Poplack DG; Glaubiger DL
Cancer Res; 1980 Jul; 40(7):2184-7. PubMed ID: 7388786
[TBL] [Abstract][Full Text] [Related]
2. Probenecid inhibition of methotrexate-cerebrospinal fluid pharmacokinetics in dogs.
Ramu A; Fusner JE; Blaschke T; Glaubiger DL
Cancer Treat Rep; 1978 Oct; 62(10):1465-70. PubMed ID: 581360
[TBL] [Abstract][Full Text] [Related]
3. Clinical pharmacology of intrathecal methotrexate. I. Pharmacokinetics in nontoxic patients after lumbar injection.
Bleyer WA; Dedrick RL
Cancer Treat Rep; 1977 Jul; 61(4):703-8. PubMed ID: 577895
[TBL] [Abstract][Full Text] [Related]
4. Therapeutic drug monitoring of methotrexate in cerebrospinal fluid after systemic high-dose infusion in children: can the burden of intrathecal methotrexate be reduced?
Niemann A; Mühlisch J; Frühwald MC; Gerss J; Hempel G; Boos J
Ther Drug Monit; 2010 Aug; 32(4):467-75. PubMed ID: 20571463
[TBL] [Abstract][Full Text] [Related]
5. Effect of probenecid on ventricular cerebrospinal fluid methotrexate pharmacokinetics after intralumbar administration in nonhuman primates.
Salzer W; Widemann B; McCully C; Adamson PC; Balis FM
Cancer Chemother Pharmacol; 2001 Sep; 48(3):235-40. PubMed ID: 11592346
[TBL] [Abstract][Full Text] [Related]
6. A primate model for study of methotrexate pharmacokinetics in the central nervous system.
Poplack DG; Bleyer WA; Wood JH; Kostolich M; Savitch JL; Ommaya AK
Cancer Res; 1977 Jul; 37(7 Pt 1):1982-5. PubMed ID: 405092
[TBL] [Abstract][Full Text] [Related]
7. Distribution and degradation of [3H]methotrexate after intravenous and cerebral intraventricular injection in primates.
Kimelberg HK; Biddlecome SM; Bourke RS
Cancer Res; 1977 Jan; 37(1):157-65. PubMed ID: 401470
[TBL] [Abstract][Full Text] [Related]
8. Methotrexate distribution within the subarachnoid space after intraventricular and intravenous administration.
Balis FM; Blaney SM; McCully CL; Bacher JD; Murphy RF; Poplack DG
Cancer Chemother Pharmacol; 2000; 45(3):259-64. PubMed ID: 10663645
[TBL] [Abstract][Full Text] [Related]
9. [Cerebrospinal fluid methotrexate level in children treated with medium-high and high doses of the drug].
Wysocki M; Balcar-Boroń A; Krzyzanowski M; Szadujkis-Szadurski L; Ozyński T; Nowaczyk-Michalak A
Acta Haematol Pol; 1992; 23(3):185-90. PubMed ID: 1492543
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of renal tubular transport of methotrexate by probenecid.
Bourke RS; Chheda G; Bremer A; Watanabe O; Tower DB
Cancer Res; 1975 Jan; 35(1):110-6. PubMed ID: 1109785
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetics of methotrexate and 7-hydroxymethotrexate following infusions of high-dose methotrexate.
Breithaupt H; Küenzlen E
Cancer Treat Rep; 1982 Sep; 66(9):1733-41. PubMed ID: 6956440
[TBL] [Abstract][Full Text] [Related]
12. Comparative effects of citrovorum factor and carboxypeptidase G1 on cerebrospinal fluid-methotrexate pharmacokinetics.
Abelson HT; Ensminger W; Rosowsky A; Uren J
Cancer Treat Rep; 1978 Oct; 62(10):1549-52. PubMed ID: 309355
[TBL] [Abstract][Full Text] [Related]
13. Distribution of methotrexate in the cerebrospinal fluid and brain after intraventricular administration.
Blasberg RG; Patlak CS; Shapiro WR
Cancer Treat Rep; 1977 Jul; 61(4):633-41. PubMed ID: 406996
[No Abstract] [Full Text] [Related]
14. Methotrexate: distribution in cerebrospinal fluid after intravenous, ventricular and lumbar injections.
Shapiro WR; Young DF; Mehta BM
N Engl J Med; 1975 Jul; 293(4):161-6. PubMed ID: 806016
[TBL] [Abstract][Full Text] [Related]
15. [Pharmacokinetics of intrathecal chemotherapy and clinical problems].
Fujimoto T
Gan To Kagaku Ryoho; 1984 Aug; 11(8):1536-42. PubMed ID: 6433796
[TBL] [Abstract][Full Text] [Related]
16. Cerebral subarachnoid sampling of cerebrospinal fluid in the rhesus monkey.
Bacher JD; Balis FM; McCully CL; Godwin KS
Lab Anim Sci; 1994 Apr; 44(2):148-52. PubMed ID: 8028278
[TBL] [Abstract][Full Text] [Related]
17. Effect of probenecid on cerebrospinal fluid methotrexate kinetics.
Howell SB; Olshen RA; Rice JA
Clin Pharmacol Ther; 1979 Nov; 26(5):641-6. PubMed ID: 498706
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of methotrexate transport from cerebrospinal fluid by probenecid.
Spector R
Cancer Treat Rep; 1976 Jul; 60(7):913-6. PubMed ID: 1009521
[TBL] [Abstract][Full Text] [Related]
19. Effects of probenecid on brain-cerebrospinal fluid-blood distribution kinetics of E-Delta 2-valproic acid in rabbits.
Scism JL; Powers KM; Artru AA; Chambers AC; Lewis L; Adkison KK; Kalhorn TF; Shen DD
Drug Metab Dispos; 1997 Dec; 25(12):1337-46. PubMed ID: 9394022
[TBL] [Abstract][Full Text] [Related]
20. Methotrexate cerebrospinal fluid and serum concentrations after intermediate-dose methotrexate infusion.
Evans WE; Hutson PR; Stewart CF; Cairnes DA; Bowman WP; Rivera G; Crom WR
Clin Pharmacol Ther; 1983 Mar; 33(3):301-7. PubMed ID: 6600662
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
